You would now be aware of the worldwide shortage of the non-ionic iodinated contrast agents Omnipaque (Iohexol) and Visipaque (Iodixanol), both supplied in Australia by GE Healthcare as a consequence of the lockdown of GE Healthcare’s factory in Shanghai, China as a result of the Covid 19 outbreak in Shanghai.
While health jurisdictions are currently attempting to source supplies of the alternative iodinated contrast agents Ultravist (Iopromide) and Optiray (Ioversol), supply is likely to be limited.
Click here to read an advisory from the ANZSVS for consideration to assist in managing the limited access to non-ionic iodinated contrast.
The advisory is of a general nature and you should consider all elements of patient care in managing the need for contrast administration for your patient with vascular disease.